Ketamine Therapy for Depression: The First Legal Psychedelic Medicine Explained

Ketamine is already legal. FDA-approved. Available in clinics across the United States. It produces antidepressant effects within hours of a single infusion. It is the first proof of concept that rapid-acting psychedelic medicine works — and it arrived years before psilocybin.

What Ketamine Actually Is

Ketamine was developed in 1962 as a dissociative anesthetic — a compound that produces a trance-like state, pain relief, and sedation without suppressing breathing. It has been used in surgical settings for decades and is on the WHO's list of essential medicines.

At sub-anesthetic doses, ketamine produces a dissociative experience — a sensation of detachment from the body and surroundings, altered perception of time, and sometimes profound introspective states. At high doses, the "K-hole" — a state of complete dissociation and depersonalization — is well-documented in recreational use.

Ketamine is not a classic psychedelic. It does not primarily target serotonin receptors. It works through NMDA receptor antagonism — blocking glutamate receptors — producing a different altered state than psilocybin or LSD. But its therapeutic effects on depression are real, rapid, and increasingly well-documented.

The FDA Approval

In 2019, the FDA approved esketamine nasal spray — brand name Spravato, manufactured by Johnson & Johnson — for treatment-resistant depression. This was the first approval of a psychedelic-adjacent compound specifically for depression.

The approval was granted to esketamine specifically — the S-enantiomer of ketamine — rather than ketamine itself. This distinction matters commercially (Johnson & Johnson can patent esketamine) but not experientially. IV ketamine infusions and esketamine nasal spray produce similar clinical outcomes. Most ketamine clinics use IV racemic ketamine because it is generic, off-label, and less expensive than Spravato.

The FDA approval changed the landscape. Ketamine clinics opened across the US. Insurance coverage for Spravato became available for qualifying patients. The regulatory proof of concept — that a dissociative/psychedelic compound can receive FDA approval for depression — was established.

How It Works

The mechanism is distinct from SSRIs and from psilocybin. Ketamine blocks NMDA receptors, which produces a rapid surge in glutamate — the brain's primary excitatory neurotransmitter. This glutamate surge triggers a cascade: increased AMPA receptor activity, release of BDNF (brain-derived neurotrophic factor), and rapid synaptogenesis — the growth of new synaptic connections.

The BDNF release and synaptogenesis are the most important part. Depression is associated with reduced synaptic density — the depressed brain has literally fewer connections than the healthy brain. Ketamine rapidly reverses this. The effect is measurable within hours and persists for days to weeks after a single infusion.

This mechanism is why ketamine works so fast. SSRIs require weeks because their mechanism — increasing serotonin availability — triggers downstream gene expression changes that take time to accumulate. Ketamine's mechanism produces structural brain changes on a different timescale.

Ketamine proved the concept. A substance that produces altered consciousness can produce rapid, significant antidepressant effects when nothing else has worked. The FDA approval of esketamine in 2019 was the regulatory crack in the wall that everything else is flowing through.

The Results

Response rates vary across studies and patient populations. In treatment-resistant depression — patients who have failed two or more antidepressant trials — ketamine produces clinically significant response in approximately 50-70% of patients in the days following infusion.

The limitation: the effect is not durable without maintenance. Unlike psilocybin, which appears to produce lasting change from one to three sessions, ketamine's effects typically fade over one to three weeks. Most ketamine treatment protocols involve an initial series of six infusions over two to three weeks, followed by maintenance infusions as needed.

This maintenance requirement is both a limitation and a feature: patients can titrate ongoing treatment to their needs in a way that psilocybin's one-session model doesn't permit.

The Experience

Ketamine's dissociative experience is distinct from classic psychedelic states. There are no visual hallucinations in the conventional sense. The experience is more like a profound shift in the sense of self and body — floating, detachment, a sense that ordinary concerns have receded to a great distance.

Many patients find the ketamine experience neutral to pleasant. Some find it disorienting. Unlike psilocybin, it rarely produces intense emotional processing or contact with what feels like external intelligence. It is more likely to produce peaceful dissociation than transformative insight.

This quality makes ketamine more accessible for patients who find the prospect of a full psychedelic experience overwhelming.

Cost and Access

IV ketamine infusions cost approximately $400-800 per infusion, with an initial series of six infusions running $2,400-4,800. Insurance occasionally covers Spravato (esketamine) but rarely covers IV ketamine, which is prescribed off-label. The cost barrier is significant and limits access for populations with the greatest need.

Ketamine clinics have proliferated rapidly following the Spravato approval. Quality varies significantly. Look for clinics that include psychological support alongside the infusions — the evidence suggests integration of the ketamine experience improves outcomes.

How Ketamine Opened the Door

The Spravato approval was, as much as anything, a proof of regulatory concept. An altered-consciousness-producing compound received FDA approval for a psychiatric indication. The FDA review process generated protocols for evaluating psychedelic medicines. The blinding challenges, patient monitoring requirements, and risk management frameworks developed for ketamine have informed the psilocybin and MDMA clinical trial designs that followed.

Ketamine normalized the category. When the FDA subsequently reviewed psilocybin's Breakthrough Therapy applications, the agency was not evaluating a completely unprecedented drug class. It was evaluating the next compound in a category whose regulatory pathway ketamine had opened.

The Technospermia Connection

Ketamine is synthetic — it does not grow in a plant or fungus. But it targets a receptor system (NMDA/glutamate) that produces antidepressant effects through mechanisms that converge with those of the serotonergic psychedelics: neuroplasticity, synaptic reorganization, relief from rigid depressive patterns.

Different molecular key. Same lock. The fact that two completely different compounds — one natural, one synthetic; one serotonergic, one glutamatergic — both produce rapid antidepressant effects through neural reorganization suggests something about what depression is and what consciousness requires to heal it.

Read the psilocybin therapy research for the serotonergic comparison, MDMA therapy for the trauma-specific evidence, or the psychedelic renaissance article for how all of this connects.